CLL geassocieerde studies

Open studies

Naam BGB-11417-303
Titel

A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Populatie Relapse / refractory CLL
Deelnemers Flevoziekenhuis - Kater / de Heer
Naam BGB-16673-304
Titel A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Pirtobrutinib in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors
Populatie Relapse / refractory CLL
Deelnemers Universitair Medisch Centrum Utrecht - De Haart
Universitair Medisch Centrum Groningen – Bellido
Albert Schweitzer Ziekenhuis – Levin
Canisius Wilhelmina Ziekenhuis – De Jonge
Groene Hart Ziekenhuis – Levenga
Catharina Ziekenhuis - Nijziel
Documenten In- en exclusiecriteria
Naam BGB-16673-302
Titel A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors
Populatie Relapse / refractory CLL
Deelnemers AmsterdamUMC - Kater
Documenten In- en exclusiecriteria
Naam BGB-11417-304
Titel A Phase 3, Open-Label, Randomized Study of Sonrotoclax-Zanubrutinib vs Venetoclax-Acalabrutinib in Treatment naive Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Populatie Treatment naive CLL
Deelnemers Flevoziekenhuis - Kater / de Heer
Hagaziekenhuis - Kersting
Albert Schweitzer Ziekenhuis – Levin
Documenten In- en exclusiecriteria
 Naam M18-803 T-PLL
 Titel A Prospective, Open-Label, Single-Arm, Phase 2, Multicenter Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects with T-Cell Prolymphocytic Leukemia
 Referentie Clinicaltrials.gov: NCT03873493
 Status Open
 Deelnemers M. Bellido, Universitair Medisch Centrum, Groningen; m.bellido@umcg.nl
L. Tick, Maxima Medisch Centrum, Eindhoven; l.Tick@mmc.nl
 Documenten In- en exclusiecriteria
Naam ACE-CL-312
Titel A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia
Referentie Clinicaltrials.gov: NCT04008706
Status Open only for patients with prior BTKi therapy (Cohort3) (Other cohorts: Treatment-naive patients and enrollment of patients with Relapsed/Refractory disease are complete)
Deelnemers Open in:
Universitair Medisch Centrum Utrecht (Utrecht) Rogier Mous (r.mous@umcutrecht.nl)
Will also be opened in:
Albert Schweitzer Ziekenhuis (Dordrecht), Mark-David Levin
HagaZiekenhuis (Den Haag), Sabina Kersting
Rijnstate Ziekenhuis (Arnhem) Ellen vd Spek
Isala Klinieken (Zwolle), Ellen Dompeling
Documenten Flow + Eligibility criteria
Up